Tessera Therapeutics
Clinical-stage biotechnology company developing a platform for permanent genomic alterations using RNA-based 'gene writing' (TPRT) and non-viral lipid nanoparticle delivery to advance in vivo genetic medicines for monogenic and other diseases.
Industries
Nr. of Employees
large (251-1000)
Tessera Therapeutics
Cambridge, Massachusetts, United States, North America
Patents
Products
TSRA-196 (investigational in vivo gene editing therapy)
An investigational in vivo RNA-based gene editing candidate designed to correct the pathogenic mutation in SERPINA1 for treatment of alpha-1 antitrypsin deficiency using a gene writing approach and LNP delivery.
Gene Writing
Proprietary technology and LNP delivery system designed to alter the human genome and effect precise, durable therapeutic change.
TSRA-196 (investigational in vivo gene editing therapy)
An investigational in vivo RNA-based gene editing candidate designed to correct the pathogenic mutation in SERPINA1 for treatment of alpha-1 antitrypsin deficiency using a gene writing approach and LNP delivery.
Gene Writing
Proprietary technology and LNP delivery system designed to alter the human genome and effect precise, durable therapeutic change.
Services
Collaborative development of gene writing and non‑viral delivery technologies with biopharma partners, including co-development and shared development-cost agreements.
Design and conduct of preclinical in vivo efficacy, durability and safety studies in rodents and non-human primates to advance programs toward IND-enabling data packages.
Formulation and optimization of targeted lipid nanoparticle systems for systemic and extra‑hepatic delivery of RNA payloads to specific cell types.
Collaborative development of gene writing and non‑viral delivery technologies with biopharma partners, including co-development and shared development-cost agreements.
Design and conduct of preclinical in vivo efficacy, durability and safety studies in rodents and non-human primates to advance programs toward IND-enabling data packages.
Formulation and optimization of targeted lipid nanoparticle systems for systemic and extra‑hepatic delivery of RNA payloads to specific cell types.
Expertise Areas
- RNA-based genome writing
- In vivo RNA delivery and LNP formulation
- Hematopoietic stem cell editing
- In vivo CAR‑T cell generation
Key Technologies
- Target-primed reverse transcription (TPRT)-based gene writing
- All‑RNA therapeutic constructs
- Lipid nanoparticle (LNP) delivery systems
- Targeted LNPs for extra‑hepatic delivery (HSCs, T cells, liver)
News & Updates
Appointment of Joseph Romanelli as President and CEO; signals leadership transition as the company advances gene writing toward clinical pipeline expansion.
Presentation of preclinical data in non-human primates showing high levels of HBB editing in LT‑HSCs and first demonstration of permanent CAR integration and functional in vivo CAR‑T generation.
U.S. FDA cleared the IND for TSRA-196, the company's lead in vivo gene editing program for alpha-1 antitrypsin deficiency; Australian HREC approval also received to begin Phase 1/2.
U.S. FDA granted Fast Track and Orphan Drug designations to TSRA-196 for treatment of adults with AATD (PiZZ genotype).
Global collaboration with Regeneron to co-develop and commercialize TSRA-196 with shared development costs and an upfront/equity investment to Tessera.
Grant funding to evaluate multiple in vivo gene writing strategies to engineer immune cells and explore scalable cures for HIV.
Appointment of Joseph Romanelli as President and CEO; signals leadership transition as the company advances gene writing toward clinical pipeline expansion.
Presentation of preclinical data in non-human primates showing high levels of HBB editing in LT‑HSCs and first demonstration of permanent CAR integration and functional in vivo CAR‑T generation.
U.S. FDA cleared the IND for TSRA-196, the company's lead in vivo gene editing program for alpha-1 antitrypsin deficiency; Australian HREC approval also received to begin Phase 1/2.
U.S. FDA granted Fast Track and Orphan Drug designations to TSRA-196 for treatment of adults with AATD (PiZZ genotype).
Global collaboration with Regeneron to co-develop and commercialize TSRA-196 with shared development costs and an upfront/equity investment to Tessera.
Grant funding to evaluate multiple in vivo gene writing strategies to engineer immune cells and explore scalable cures for HIV.